Actionable news
All posts from Actionable news

Teva to Host Conference Call and Webcast to Provide Preliminary Outlook for 2016-2019

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host a conference call and webcast for the investment community on Wednesday, July 13, 2016 at 8:00 a.m. ET to communicate its preliminary non-GAAP financial results for the quarter ended June 30, 2016. The Company will also provide its preliminary non-GAAP financial outlook for the years 2016 - 2019, which will include its pending acquisition of the Actavis Generics business that is awaiting FTC clearance.

On the conference call and webcast, the Company will communicate that it now expects revenues for the second quarter of 2016 to be $4.9 – $5.0 billion compared to its previous guidance of $4.8 – $4.9 billion, while non-GAAP EPS for the quarter is now expected to be $1.19 – $1.22 compared to the previous guided range of $1.16 – $1.20 based on a fully diluted weighted average number of shares of 980 million. Cash flow from operating activities is now expected to be $1.0 – $1.1 billion compared to $1.2 – $1.3 billion.

In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-254-0808; Canada 1-866-607-2172 or International +44(0) 1452-541003; passcode: 46404463. For a list of other international toll-free numbers, click here.

A live webcast of the call will also be available on Teva's website at: Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

Following the conclusion of the call, a replay of the webcast will be available within 24 hours on the Company's website. The replay can also be accessed until August 8, 2016, 9:00 a.m. ET by calling United States 1-866-247-4222; Canada 1-866-878-9237 or International +44(0) 1452-550000; passcode: 46404463.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2015 amounted to $19.7 billion. For more information, visit

Teva's Safe Harbor...